Lopinavir
| Systematic (IUPAC) name | |
|---|---|
| (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a602015 |
| Pregnancy cat. | C (US) |
| Legal status | POM (UK) ℞-only (US) |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | Unknown |
| Protein binding | 98-99% |
| Metabolism | Hepatic |
| Half-life | 5 to 6 hours |
| Excretion | Mostly fecal |
| Identifiers | |
| CAS number | 192725-17-0 |
| ATC code | J05AR10 (with ritonavir) |
| PubChem | CID 92727 |
| DrugBank | DB01601 |
| ChemSpider | 83706 |
| UNII | 2494G1JF75 |
| KEGG | D01425 |
| ChEMBL | CHEMBL729 |
| Chemical data | |
| Formula | C37H48N4O5 |
| Mol. mass | 628.810 g/mol |
|
|
|
|
| |
|
Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is used as a fixed-dose combination with another protease inhibitor, ritonavir, under the trade names Kaletra (high-income countries) and Aluvia (low-income countries).
Contents |
Pharmacology [edit]
Lopinavir is highly bound to plasma proteins (98–99%).[1]
There are contradictory reports regarding lopinavir penetration into the cerebrospinal fluid (CSF). Anecdotal reports state that lopinavir cannot be detected in the CSF; however, a study of paired CSF-plasma samples from 26 patients receiving lopinavir/ritonavir found lopinavir CSF levels above the IC50 in 77% of samples.[2]
Clinical properties [edit]
Side effects, interactions and contraindications have only be evaluated in the drug combination lopinavir/ritonavir.
References [edit]
- ^ KALETRA (lopinavir/ritonavir) capsules; (lopinavir/ritonavir) oral solution. Prescribing information. April 2009
- ^ Capparelli E, Holland D, Okamoto C, et al. (2005). "Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV". AIDS (London, England) 19 (9).
External links [edit]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||